Radiobiological principles in intravascular irradiation

Area of Science:

• Medical Physics
• Radiation Oncology
• Cardiovascular Interventions

Background:

• Restenosis following balloon angioplasty is a significant clinical challenge.
• Smooth muscle cell (SMC) proliferation, triggered by angioplasty-induced damage, is a key mechanism in restenosis.
• Intravascular irradiation using gamma-rays or beta-rays has shown potential to inhibit SMC proliferation and control restenosis.

Purpose of the Study:

• To model the control of restenosis using in vitro data on SMC radiosensitivity.
• To estimate the biological effectiveness of gamma-rays versus beta-rays and the impact of exposure time on cell killing.
• To address challenges in developing beta-emitting sources for intravascular irradiation.

Main Methods:

• Utilized in vitro data on smooth muscle cell (SMC) survival following radiation exposure.
• Employed physical and biological data to model radiation effectiveness and dose-rate effects.
• Analyzed the influence of varying exposure times (1-20 min) on biological effects for single high-dose irradiations.

Main Results:

• A single acute gamma-ray dose of 15-20 Gy can inhibit restenosis based on SMC radiosensitivity.
• Successful clinical trials to date have used gamma-emitting Iridium-192, but this poses safety and time challenges.
• Beta-emitting sources are being developed to overcome these limitations, but their biological effectiveness and dose-rate dependency require further investigation.

Conclusions:

• Doses exceeding 15 Gy are expected to delay, not eliminate, restenosis, with higher doses providing longer delays.
• Current successful endovascular radiation trials utilize gamma-rays, while new systems focus on beta-emitters.
• Urgent experimental data are needed to account for differences in dose-rate and radiation quality between gamma and beta-emitting radionuclides.